Yesterday, the Department of Justice issued an order that will be described everywhere as federal cannabis “rescheduling”. It is, and it is not. Acting Attorney General Todd Blanche signed an order removing two narrow categories of marijuana from the highly-regulated Schedule I classification of controlled substances (e.g., heroin) and reassigning them to the less-regulated Schedule III classification of the Controlled Substances Act, effective April 22, 2026. These “rescheduled” controlled substances are: (1) FDA-approved drug products containing marijuana (e.g., Epidiolex), and (2) marijuana and marijuana products subject to a qualifying state-issued medical marijuana license. The order applies to marijuana as defined in the CSA, marijuana extracts, and delta-9-tetrahydrocannabinol and other compounds derived from the marijuana plant (other than mature stalks and seeds) that fall outside the definition of “hemp”. Everything else marijuana remains Schedule I – recreational or adult-use sales, cultivation, possession, and use of marijuana are still federal crimes.
The order invokes the Attorney General’s treaty authority under 21 U.S.C. § 811(d)(1), which permits scheduling (and, apparently, rescheduling) by order. This is a novel application of 811(d)(1), which has historically been invoked to impose scheduling controls required by treaty, not to partially down-schedule a substance already at Schedule I. The authority question will likely be a central issue in any litigation challenging the order. Separately, DEA withdrew the Biden-era notice of hearing and opportunity for public comment set for late 2024 (of the Administrative Procedures Act), claiming its requirements are not applicable to the order, and set a new expedited administrative hearing to begin on June 29, 2026, to “evaluate broader changes to marijuana’s status under federal law ” – meaning what? Legalization?
Implications of the Order to Medical Marijuana Businesses
Going forward (and maybe for some prior tax years), state-licensed medical operators can deduct ordinary general and administrative costs and expenses (e.g., office rentals, executive compensation, marketing service fees) because IRC § 280E applies only to trafficking in Schedule I and II substances – this is a material tax shift for medical operators that have been paying federal tax on gross profit. Cannabis research using state-available medical products becomes easier. However, the order will require federal registration with the DEA of state-licensed manufacturers, distributors, and dispensers. Schedule III dispensing of medical marijuana will now run through the federal prescription system under 21 U.S.C. § 829(b), which requires a written prescription from a medical practitioner to be filled by a DEA-registered pharmacist, calling into question the need for state medical marijuana dispensaries that are not registered pharmacies. Even at this early stage of analysis on the order, it appears that the prescription-dispensing FDA/DEA framework does not map cleanly onto existing state-licensed operations.
Implications of the Order on Recreational Marijuana
Adult-use cannabis remains an illegal Schedule I controlled substance under federal law. The order will not empty any prison cells, will not open the NYSE or Nasdaq to plant-touching operators, will not fix banking, will not permit interstate commerce, and will not cure firearms, immigration, or federal-employment consequences.
For attorneys advising plant-touching clients, the real work starts now.
Originally published April 24, 2026.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
